Summary & Overview
HCPCS Level II J1952: Leuprolide injectable (camcevi), 1 mg
HCPCS Level II code J1952 designates leuprolide injectable, camcevi, 1 mg, a GnRH agonist administered as an injectable biologic. This code is used to report the drug product itself when billed in outpatient and ambulatory settings and is relevant for clinicians, pharmacies, and payers managing specialty drug coverage and payment for hormonal therapies. Nationally, accurate use of this HCPCS Level II code affects claims processing, drug utilization tracking, and specialty pharmacy reimbursement.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for leuprolide injections, typical sites of service, and the role of this HCPCS Level II code in billing workflows. The publication summarizes coverage considerations and payer landscape at a national level, highlights typical billing and coding use cases, and outlines areas where readers may seek payer-specific policy language. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1952 represents leuprolide injectable, camcevi, 1 mg, a gonadotropin-releasing hormone (GnRH) agonist formulation used for hormonal therapy. The billing code covers the medication in injectable form and is reported per 1 mg unit as described.
Service Type: Drug administration (injectable biologic)
Typical Site of Service: Outpatient infusion clinic, physician office, or ambulatory care setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 35–65-year-old individual with prostate cancer, endometriosis, or uterine fibroids receiving therapy with leuprolide acetate (brand: Camcevi) via intramuscular or subcutaneous injection. The clinical workflow begins with the prescribing clinician (urologist, gynecologist, or reproductive endocrinologist) documenting the indication, dosing schedule (commonly monthly or every 3–6 months depending on formulation), and informed consent. On the day of service the nurse verifies identity, allergies, and current medications, prepares the J1952 single-use syringe or vial, and administers the medication using standard injection technique. Post-injection monitoring includes observation for immediate adverse reactions (15–30 minutes for high-risk patients), documentation of lot number and expiration, and patient education on expected effects (e.g., decreased sex hormone-related symptoms, potential injection-site pain). Subsequent visits include assessment of therapeutic response, management of side effects, and scheduling of the next J1952 administration visit. Typical sites of service are outpatient clinics, physician offices, ambulatory infusion centers, and hospital outpatient departments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |